Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Algernon Pharmaceuticals Secures Lead Sponsorship of 2022 Wonderland Psychedelic Conference in Miami
https://www.globenewswire.com/news-release/2022/09/08/2512310/0/en/Algernon-Pharmaceuticals-Secures-Lead-Sponsorship-of-2022-Wonderland-Psychedelic-Conference-in-Miami.html
VANCOUVER, British Columbia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce that it will be the Headline Sponsor for Wonderland, the world-leading academic and business gathering in the psychedelic medicine industry, which will be held in Miami from November 3-5th, 2022 at the Mana Wynwood Convention Centre.
Christopher J. Moreau, the Company’s CEO, will deliver two keynote addresses:
Business Session Keynote November 4th, 1:00pm EST
Science Session Keynote November 5th, 2:00pm EST
Wonderland is the world’s largest conference in the psychedelic medicine sector. It provides an opportunity to discover the world of psychedelic medicine, and is attended by some of the leading founders, investors, therapists, practitioners, researchers, thought leaders, innovators, and media from around the globe.
“We are delighted to welcome our friends at Algernon Pharmaceuticals as the lead sponsor of the conference and to have them involved with our programs,” said Patrick Moher, President of Microdose Psychedelic Insights. “Wonderland Miami is a one-of-a-kind event, and we are very pleased to continue our collaboration with Algernon Pharmaceuticals as an official headline sponsor.”
Algernon has established a clinical research program for the treatment of stroke focused on AP-188 (“N,N-Dimethyltryptamine or DMT”), a known psychedelic compound that is part of the tryptamine family (other drugs in the tryptamine family include psilocybin and psilocin).
Algernon has been laying the clinical groundwork to be the first company globally to investigate sub-psychedelic doses of DMT as a possible treatment for stroke and is planning to begin a Phase 1 clinical trial in Q4, 2022.
The Company’s decision to investigate DMT and move it into human trials for stroke is based on multiple independent, positive, preclinical studies demonstrating that DMT helps promote neurogenesis as well as structural and functional neural plasticity. These are key factors involved in the brain’s ability to form and reorganize synaptic connections, which are needed for healing following a brain injury.
The Company has now completed its intravenous formulation (“IVF”) that will be used in the Phase 1 DMT study. The formulation was developed by the Centre for Human Drug Research (“CHDR”) and its affiliated pharmacy at the Leiden University Medical Center in the Netherlands. The Company has applied for ethics and clinical trial approval and is expecting to have a response shortly.
“We are delighted to be the Headline Sponsor for the Wonderland 2022 event and have the opportunity to build a greater awareness of Algernon and our DMT stroke research program within the many different facets of the psychedelic medicine world,” said Christopher J. Moreau CEO of Algernon.
Phase 1 DMT Stroke Study Summary
The purpose of Algernon’s planned study is to identify the safety, tolerability, and pharmacokinetics of DMT when administered as an intravenous bolus followed by prolonged infusion. The first part of the study will use a single-escalating dose design while the second part will test the effects of repeated administrations of the highest safe dose. There will be up to 60 healthy volunteers enrolled across the two parts of the study which will include both psychedelic experienced and psychedelic naïve patients.
About DMT
N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug producing effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin. DMT occurs naturally in many plant species and animals including humans and has been used in religious ceremonies as a traditional spiritual medicine by indigenous people in the Amazonian basin. DMT can also be synthesised in a laboratory.
Algernon has filed provisional patents for new salt forms of DMT, in addition to formulation, dosage and method of use claims for ischemic stroke. The Company has also filed claims for combination therapy of DMT and stroke rehabilitation including Constraint Induced Movement Therapy.
About Microdose Psychedelic Insights
Microdose Psychedelic Insights aims to unlock the potential of psychedelic medicine through Industry events, market intelligence, original, evidence-based content, strategy, and community. We enable and empower society at large to make better, more mindful decisions about psychedelics and their intersection with healthcare, medicine, and personal growth. We work with the industry’s most influential stakeholders, some of the world’s best-known brands, and an unrivalled network of scientists, researchers, analysts, innovators, investors, and advisors.
About Wonderland
Wonderland offers the psychedelic medicine industry a unique in-person convergence of business, science, music, and emerging technologies. Fostering creative and professional growth, Wonderland: Miami is the premier destination for the psychedelic medicine industry. The event is a thought-leadership platform and an opportunity to connect with influential leaders in science, policy, and business. It acts as a launching pad for innovative content connected to the psychedelic medicine space, with musical showcases and documentary screenings, providing compelling entertainment and collaboration opportunities for attendees. Wonderland is all about real-life events featuring high-quality programming in some of the world's most exciting locations and breath-taking venues.
https://microdose.buzz/companies/algernon-pharmaceuticals/
Outstanding Shares 690,499,016 for 09/01/2022
https://www.otcmarkets.com/stock/MEDH/security
Outstanding: 2,357,885 on September 7, 2022
Monthly 5th Report
https://webfiles.thecse.com/8._Algernon_-_CSE_Form_7_-_August.pdf?04U6.ZVCVkMCQLecaG_HVaKC4V93PWk6
Scroll down and see Options gave and more RSU’s and all 8/31/2022 and 313,000 more Outstanding when they convert
JMO — Something to maybe wonder
The Form 10 that $AGN on CSE
$130,000 Pd to promote or handle Investor Relations @ $AGNPF, “consulting agreement, effective August 22, 2022 with GRA Enterprises LLC.”
https://webfiles.thecse.com/CSE_Form_10_-_Notice_of_Proposed_Transaction_38.pdf?DlTi8pWjdTiZsRePPFSCcgGwckBOuUky
Then looking him up from another he did the same, bought into the Placements then Pd $250K there and only cost $130K of $AGNPF money on the Placement but pushed him to grater than 10% hold $AGNPF
Here’s from another that did the same
Outstanding: 114,144,104 for September 5, 2022
Monthly 5th Report
https://webfiles.thecse.com/Cannabix_Monthly_Progress_Report_Form_7_Sep_5_2022.pdf?_cG9YmIh3Xz5ZdrWnLlJWuzsUHE6wWmP
$AGNPF up 100% from 1 Month ago
https://investorshub.advfn.com/uimage/uploads/2022/9/2/piptg0DD08D40-A6BC-43A1-9FFD-DD4CEEF0C02D.png
It’s a start — Beneficial Shareholder 1 - 09/01/2022
Scroll down and look under “Shareholders”
https://www.otcmarkets.com/stock/MEDH/security
Streetwise Reports - Expert Rates Pharma Co. An Immediate Buy
https://www.streetwisereports.com/article/2022/09/01/expert-rates-pharma-co-an-immediate-buy.html
Proactive Investors Interview - Algernon Pharmaceuticals Releases Positive Data from Study on Ifenprodil for IPF and Chronic Cough
Positive Results from Full Data Set of its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
VANCOUVER, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE)
Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to report positive results from the full data set of its Phase 2a Study evaluating NP-120 (“Ifenprodil”) for the potential treatment of idiopathic pulmonary fibrosis (“IPF”) and chronic cough.
The full data set includes additional secondary measures of efficacy, including both objective measurement of lung function and patient-reported outcomes of both IPF and cough. All of the data showed positive results, including statistically significant improvements in measures of cough.
On July 18th, the company announced top line data indicating that the study’s IPF co-primary endpoint, preservation of lung function determined by no worsening of forced vital capacity (“FVC”) over 12 weeks, had been met. The Company further reported on July 28th, significant reductions in geometric mean cough counts after both 4 and 12 weeks of treatment.
IPF Data
Secondary endpoints focused on pulmonary fibrosis, as indicated by key measures, were consistent with the preservation of lung function as measured by key indications, specifically:
Unchanged diffusing capacity for carbon monoxide (DLCO) over twelve weeks (change from baseline 0.00, p > 0.99, 95% CI -3.14, 3.14). DLCO estimates the ability of the lungs to transfer oxygen between alveolar gas and red blood cells.
No change in the modified Medical Research Council (mMRC) dyspnea scale over twelve weeks. The mMRC scale is a self-rating tool to measure the degree of disability imposed by breathlessness on day-to-day activities.
An increase of 7.0 points in the King’s Brief Interstitial Lung Disease Questionnaire (K-BILD) (p = 0.1209, 95% CI -2.03, 16.03). The K-BILD is a self-administered health-status questionnaire developed in patients with interstitial lung diseases (higher scores are better).
Cough Data
Secondary endpoints focused on cough showed significant improvements, namely:
A reduction of 23.6 mm from baseline in the cough visual analogue scale (VAS) (p = 0.0005, 95% CI -35.22, -11.94). The cough VAS is a patient-reported subjective assessment of cough severity (lower scores are better).
An improvement of 10.05 points in the mean score on the Leicester Cough Questionnaire (LCQ) (p = 0.0296, 95% CI 1.12, 18.99). The LCQ is a self-completed quality of life measure of chronic cough (higher scores are better).
Ifenprodil was well tolerated with a high overall compliance rate (average >90%). As reported with the top line data, no new safety concerns were identified.
The full results of the trial will be presented at the 21st International Colloquium on Lung and Airway Fibrosis in Reykjavik, Iceland in October 2022, and will also be discussed at the 9th American Cough Conference in Reston, Virginia in June 2023.
“The full data set is excellent,” said Dr. Martin Kolb, professor of respirology at McMaster University and global expert on IPF. “Of course, patient numbers are low, but it is encouraging to see that all is going in the right direction. This data enhances my belief that this drug merits investigation in a much larger trial.”
“This data, when added to the topline data already reported, now provides a more complete picture that shows just how effective Ifenprodil was in this Phase 2a study,” said Christopher J. Moreau CEO of Algernon. “We look forward to presenting the data to the U.S FDA, including applying for orphan designation, the filing of a pre-IND application for a Phase 2b IPF with cough trial, as well as an application for Breakthrough Therapy designation.”
The Company also announces a grant of 221,000 restricted share units pursuant to its RSU Plan (each, an "RSU") to executives, directors, employees and consultants of the Company. Each RSU entitles the recipient to receive one common share of the Company or a cash payment equal to the equivalent for one common share of the Company on vesting. The RSUs vest one-third on January 1, 2023, one-third on June 1, 2023, and one-third on January 1, 2024.
The Company has also granted 92,000 stock options exercisable at $5.39 for five years from date of grant, to officers, directors, employees and consultants of the Company. The stock options vest 50% on the grant date and 50% on February 28, 2023.
The RSUs and stock options are subject to approval by regulatory authorities.
About Ifenprodil
Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B). Ifenprodil prevents glutamate signalling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils. Ifenprodil represents a novel first in class treatment for both IPF and chronic cough.
https://www.globenewswire.com/search/keyword/Algernon%252520Pharmaceutical
We break the 200 Day and expect it to go Higher
https://investorshub.advfn.com/uimage/uploads/2022/8/26/iqvksDCE6B41A-44E7-4846-8200-32CC8736FBCA.png
Here’s where $AGNPF is at now
https://investorshub.advfn.com/uimage/uploads/2022/8/26/iqvksDCE6B41A-44E7-4846-8200-32CC8736FBCA.png
Break the 200 Day and 10% holder outside Company Holds on to their 10% — I hope and believe their adding to their Hold but they also gathered the most 8% Cash and 8% shares payment but also gather another 8% in cheap Warrants of $4.10 vs $4.75 warrants they bought - Bought and Holding
P.s. - In the past of AGNPF or BreathTec — Warrants only once touched the Warrants Price or should say the Warrants were bought and Forced on That — Todays or these last have a $12 or $16 strike price on a CAD price or $AGN price
Cannabix Technologies Correlates THC in Breath and Blood using Proprietary Sample Collection and Analysis Hardware in Southern US Study
https://www.otcmarkets.com/stock/BLOZF/news/story?e&id=2304997
Largest Shareholder AlphaNorth Asset Management Increases Ownership Position
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Largest-Shareholder-AlphaNorth-Asset-Management-Increases-Ownership-Position?id=369760
Victor Lazzaro Jr. was 2008 here or was Disaboom before couple name changes to $MEDH
Here’s his LinkedIn page and lists Disaboom's from 2006-2010 on his Experience page
If I was him, I’d go after you
https://www.linkedin.com/in/victor-lazzaro-179b804
P.S. —. CEO tweet 30 Hrs ago of $DAZE coming here as another Symbol and Name Change coming
Name change and ticker change on the way. @DazedBrands $DAZE#CannabisNews #OTCnews #CannabisCommunity #Legalizecannabis PR news on the way. Stand by. Let's get eyes on our company create Investor and Brand awareness. Lounges will be critical to legalization. pic.twitter.com/jyXHNXsWtM
— the 1 & Only HANS (@The1OnlyHans) August 21, 2022
outstanding securities following issuance: 2,357,885
https://webfiles.thecse.com/Algernon_CSE_Form_9_-_Aug_2022.pdf?mHI4l86yb0_fxa3SlzAAiWIUnW2rL1de
MD&A filed 08/17/2022 for Year End 04/30/2022
https://webfiles.thecse.com/2022_MDA_Cannabix.pdf?NO1J3EW3niV6.wwYCyt9zC83lEKgo8kj=
Algernon Pharmaceuticals Announces Private Placement
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-Private-Placement?id=369254
Algernon Rapidly Advances Clinical Trials For Two Lead Programs
https://www.medicalgold.ca/companies/algernon-pharmaceuticals
JMO on Highlights of 2Q Filing
08/16/2022 — Quarterly Report 06-30-22
https://www.otcmarkets.com/otcapi/company/financial-report/343398/content
Outstanding: 1,983,985 on August 8, 2022
Monthly 5th Report has Posted
https://webfiles.thecse.com/7._Algernon_-_CSE_Form_7_-_July.pdf?1kpJotmjV4auNosKqpV4KhIZOGlUuXMi
Needs to File 2Q by Monday
Outstanding: 1,983,985 on August 8, 2022
Monthly 5th Report has Posted
https://webfiles.thecse.com/7._Algernon_-_CSE_Form_7_-_July.pdf?1kpJotmjV4auNosKqpV4KhIZOGlUuXMi
Outstanding: 114,144,104 for August 5, 2022
Monthly 5th Report
https://webfiles.thecse.com/Cannabix_Monthly_Progress_Report_Form_7_Aug_5_2022.pdf?1cHUInDJX3qtu3n1lqoxkIY2R4KzaI3U
Highlights:
Issued & Outstanding: 1,983,985
Reserved for Issuance: 624,206
Waiting the Monthly Report but shows CSE that posted above
https://www.thecse.com/en/listings/life-sciences/algernon-pharmaceuticals-inc
Wish I could slap the 10M sitting on the Ask from .0022-.0024
ORCA — Slap it please
$DAZE us
Or somebody-anybody please $DAZE us
JMO — Shorts would spark and maybe just maybe have to chase when approved $DAZE hits the OTC Screen
Quick update. TEAM $medh
DAZED INC is now at @DazedBrands
Medx Holdings TW acct has been deleted.
Onward!!
Quick update. TEAM $medh
— the 1 & Only HANS (@The1OnlyHans) August 2, 2022
DAZED INC is now at @DazedBrands
Medx Holdings TW acct has been deleted.
Onward!!
Those short shares could push $DAZE there with Symbol Change
The Short with MM’s Air-Shares with knowledge of Miller Games, they knew of the game and under-sell knowing of Millers dump but I don’t think any dump of the last 350,000,000 he received, might even see a Cancel of those shares making roughly 350,000,000 Outstanding and Hans with 600,000,000 if he converts making 950,000,000 (if he Converts) and then the 1,000,000,000 Authorized number work
I don’t think we’ll see any dilution from here — JMO
Hey Hey Hey! New Cusip# request accepted today! Name change $daze upon approval. $medh Team
@DazedCorp
#20milemarch everyday
https://mobile.twitter.com/The1OnlyHans
Power Play by Market Herald Interviews Christopher J. Moreau, CEO, Algernon Pharmaceuticals
https://cdn.jwplayer.com/previews/zuXtp5J0
(CSE:AGN) achieves co-primary endpoint in its Phase 2 study of Ifenprodil
Christopher J. Moreau, CEO of Algernon Pharmaceuticals, sat down with Sabrina Cuthbert of The Power Play to discuss an important update.
Algernon Pharmaceuticals (AGN) has met the co-primary endpoint in its Phase 2 proof of concept study evaluating NP-120 (Ifenprodil).
Ifenprodil is being evaluated for the potential treatment of idiopathic pulmonary fibrosis (“IPF”) and chronic cough.
Based on the positive data, the company plans to file a pre-IND application with the U.S. FDA for a Phase 2b IPF study. The Phase 2b study will also have multiple arms, multiple doses, would be placebo controlled and would be double blinded and randomized.
For chronic cough, Algernon has already filed a pre-IND application with the U.S. FDA and has announced that it has received positive feedback.
Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications.
For trading information on the Company please visit Algernon Pharmaceuticals Inc. (AGN).
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com
Outstanding Shares 261,666,851 posted 07/15/2022
https://www.otcmarkets.com/stock/CNNA/security
Inaugural Women’s CannaCup Powered By CannaGram Launches
https://www.otcmarkets.com/stock/CNNA/news/Cann-American-Corp-Partner-Cannagram-Featured-at-California-State-Fair?id=364966
https://www.digitaljournal.com/pr/inaugural-womens-cannacup-powered-by-cannagram-launches
Wyoming Secretary of State already changed the Name from MedX Holdings to Dazed, Inc. and Symbol Change is coming next to hopefully $DAZE — Like it or not — Stock Gonna Move and I know you just gonna watch it go Higher without owning Shares
Here’s one for the Heatwave claiming most Southern States
Shorts PdGood for info which those he speaks of have left $MEDH
But I would think the 600,000,000 shares to those he speaks about with these to Miller himself after facing already Federal Charges are probably not sold but MM’s Air-Shares dumped waiting for Miller to dump with MM’s taking their slice
Symbol Change from $MEDH to hopefully $DAZE will change the direction of the Shorts - There Always be a Short but probably once Silver this next time
7/1/2021
New issuance
209,500,000
Common
$ 0.0002
Capitol Capital Corp (Mark Miller)
7/20/2021
New issuance
45,000,000
Common
$ 0.0002
Capitol Capital Corp (Mark Miller)
8/6/2021
New issuance
22,500,000
Common
$ 0.0002
Capitol Capital Corp (Mark Miller)
8/27/2021
New issuance
60,000,000
Common
$ 0.0002
Capitol Capital Corp (Mark Miller)
10/20/2021
New issuance
15,000,000
Common
$ 0.0001
Capitol Capital Corp (Mark Miller)
345,000,000 off the 600,000,000 to those were after facing 43 Federal Charges for same kind of game by Mark Miller
I think we’ll all someday here@ $Dazed, Inc — We’ll Hear the real story from Hans one day - Hope so anyway — Probably a gag deal till all is done
And I’d love to see the 345,000,000 miller hold be wiped making 350,000,000 outstanding and the others that hold roughly 260,000,000 also be wiped but probably those were played with SEC watching already Gary Kouletas which he was issued
07/01/2020
New Issuance
60,000,000
Common
.001 Yes
PAG Group Gary Kouletas
He was facing Federal Charges about a Month after that for another group that had like 8 folks under Federal Charges
9 Months later Mark Miller with another fellow getting $MEDH shares but for other Company’s the Charges
I think $MEDH with Hans help to put the Nails in the Coffin for Miller and Saied Jaberian
JMO - Hans with 60,000,000 Prefferds that convert if he wants to 600,000,000 Commons if he wants — 1B Authorization works with Cancelation of that 600,000,000 Issued to those facing Charges
OTC Lottery Play with Hans calling Numbers someday
New Look —> Dazed, Inc.
https://www.dazedinc.com/about-dazedinc
Breathing Easier - Liftoff! - IPF Phase 2a Data Hits
ACTION: Maintaining SPECULATIVE BUY Rating and Target Price AGN reported topline results of a Phase 2a trial with ifenprodil in IPF patients with chronic cough - the idiopathic pulmonary fibrosis (IPF) data hit its endpoint -showing promising initial efficacy. We are maintaining a SPECULATIVE BUY rating. Our target price of C$25.00 is based on a probability-adjusted NPV analysis of ifenprodil.
DETAILS: Topline Phase 2a Results with Ifenprodil in IPF Patients with Chronic Cough
Design of the Trial: This open-label study enrolled 20 idiopathic pulmonary fibrosis (IPF) patients with chronic cough. Each patient received 12 wks of ifenprodil treatment (20mg, 3 times/day). The primary endpoints...
https://mcusercontent.com/801eef9c534139834fde0ed02/files/5be4e3af-7e46-0f39-52c8-39a4c65a95d1/Reasearch_Capital_Corp_Algernon_Update_July_18_.pdf